Michael Wang, MD, on Mantle Cell Lymphoma: New Results on Ibrutinib Plus Venetoclax
2023 ASH
Michael Wang, MD, of The University of Texas MD Anderson Cancer Center, discusses phase III results from the Sympatico study, which shows the combination of ibrutinib and venetoclax improved progression-free survival vs ibrutinib plus placebo in patients with relapsed or refractory mantle cell lymphoma. According to Dr. Wang, these findings demonstrate a favorable benefit-risk profile for ibrutinib plus venetoclax in this patient population (Abstract LBA2).
The ASCO Post Staff
Jeffrey E. Rubnitz, MD, PhD, of St. Jude Children’s Research Hospital, discusses study findings suggesting that pharmacogenomic differences between Black and White patients should be considered when tailoring induction regimens to improve outcomes of all patients and bridge the racial disparity gap in acute myeloid leukemia treatment (Abstract 386).
The ASCO Post Staff
Pieter Sonneveld, MD, PhD, of the Netherland’s Erasmus MC Cancer Institute, discusses primary results from the Perseus trial, showing that for patients with newly diagnosed multiple myeloma who are eligible for transplantation, the combination of daratumumab plus bortezomib, lenalidomide, and dexamethasone, followed by daratumumab and lenalidomide maintenance, may be a new standard of care (Abstract LBA1).
The ASCO Post Staff
Ibrahim Aldoss, MD, of City of Hope National Medical Center, discusses phase II safety and efficacy results from the Augment-101 study. This trial showed that patients with heavily pretreated, relapsed or refractory KMT2-rearranged acute leukemia benefited from monotherapy with the menin-KMT2A inhibitor revumenib, with high overall response rates and undetectable measurable residual disease (Abstract LBA-5).
The ASCO Post Staff
Hamish S. Scott, PhD, and Chris Hahn, PhD, both of Australia’s SA Pathology and Centre for Cancer, discuss ERG, a new predisposition gene for bone marrow failure and hematologic malignancy. Identifying causal germline ERG variants has direct clinical implications for diagnosis, counseling, surveillance, and treatment strategies, according to Drs. Scott and Hahn (Abstract LBA5).
The ASCO Post Staff
Jennifer A. Woyach, MD, of The Ohio State University Comprehensive Cancer Center, discusses phase I/II findings of the BRUIN study on the use of pirtobrutinib after covalent Bruton’s tyrosine kinase (BTK) inhibitors in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). The results suggest that continuing BTK pathway inhibition following a covalent BTK inhibitor may be an important sequencing approach to consider in the treatment of CLL/SLL (Abstract 325).
